Refractory Cytopenia With Multilineage Dysplasia

Watchlist
Retrieved
2021-01-23
Source
Trials
Drugs

Refractory cytopenias with multilineage dysplasia (RCMD) is a frequent subtype of myelodysplastic syndrome (MDS; see this term) characterized by 1 or more cytopenias in the peripheral blood and dysplasia in 2 or more myeloid lineages.

Epidemiology

Exact prevalence is unknown but RCMD accounts for about 30% of patients with MDS which has a prevalence estimated to be 1/25,000 to 1/33,000. The disease tends to occur in older adults with a male predominance.

Clinical description

Most patients are asymptomatic at presentation, and the disorder is detected incidentally. Some patients may have fatigue (anemia), a tendency to bleed or bruise (thrombocytopenia), or susceptibility to infections (neutropenia). Laboratory findings show one or more cytopenias.

Etiology

The etiology is not known but is thought to involve inherited susceptibility or hematopoietic stem cell damage.

Diagnostic methods

The hematological parameters used to define RCMD are as follows: less than 1% blasts in peripheral blood or less than 5% in bone marrow, multilineage dysplasia sometimes with ring sideroblasts, and no Auer rods (abnormal, needle-shaped or round inclusions in the cytoplasm of myeloblasts and promyelocytes).

Prognosis

Median survival of 17 to 33 months has been reported.